CD34+ cell selection using small-volume marrow aspirates: A platform for novel cell therapies and regenerative medicine

Cytotherapy

Volumn 12, Issue 2, 2010, Pages 170-177

  McKenna Jr , David H ^a   Adams, Sheryl ^a   Sumstad, Darin ^a   Sumstad, Therese ^a,f   Kadidlo, Diane ^a   Gee, Adrian P ^b   Durett, April ^b   Griffin, Debe ^c   Donnenberg, Albert ^c   Amrani, David ^d   Livingston, Deborah ^d   Lindblad, Robert ^e   Wood, Deborah ^e   Styers, David ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d BAXTER HEALTHCARE CORPORATION   (United States)

^e EMMES CORPORATION   (United States)

^f Minnesota Oncology   (United States)

Author keywords

Bone marrow; Cell therapy; Regenerative medicine

Indexed keywords

REAGENT;

ARTICLE; BONE MARROW; CD34 SELECTION; CELL COUNT; CELL THERAPY; CELL VIABILITY; CELL VOLUME; COLONY FORMING UNIT GM; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; REGENERATIVE MEDICINE;

EID: 77749254969     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653240903476446     Document Type: Article

References (15)

1. Appelbaum FR. Hematopoietic cell transplantation at 50. New Engl J Med. 2007;357:1472-5.
2. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-86.
3. Lanzoni G, Roda G, Belluzzi A, Roda E, Bagnara GP. Inflammatory bowel disease: moving toward a stem cell-based therapy. World J Gastroenterol. 2008;14:4616-26.
4. García-Castro J, Trigueros C, Madrenas J, Pérez- Simón JA, Rodriguez R, Menendez P. Mesenchymal stem cells and their use as a cell replacement therapy and disease modeling tool. J Cell Mol Med. 2008;12:2552-65.
5. Reffelmann T, Könemann S, Kloner RA. Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair. J Am Coll Cardiol. 2009; 53:305-8.
6. Capiod JC, Tournois C, Vitry F, Sevestre MA, Daliphard S, Reix T, et al. Characterization and comparison of bone marrow and peripheral blood mononuclear cells used for cellular therapy in critical leg ischaemia: towards a new cellular product. Vox Sang. 2009;96:256-65.
7. Moviglia GA, Varela G, Brizuela JA, Moviglia Brandolino MT, Farina P, Etchegaray G, et al. Case report on the clinical results of a combined cellular therapy for chronic spinal cord injured patients. Spinal Cord. 2009;46: 499-503.
8. Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bruyne B, De Bondt P, et al. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation. 2005;112 (suppl 9): 1178-83.
9. + cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996;5: 213-26.
10. + cells: factors influencing component purity and yield. Transfusion. 2000;40: 507-12.
11. + hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients. Biol Blood Marrow Transplant. 2007;13:608-14.
12. + cells from blood stem cell components using the Baxter Isolex system. Bone Marrow Transplant. 1998;21:1253-62.
13. + peripheral blood stem cells using the Baxter Isolex 300i. J Hematother Stem Cell Res. 2002;11:719-30.
14. Laroche V, McKenna DH, Moroff G, Schierman T, Kadidlo D, McCullough J. Cell loss and recovery in umbilical cord blood processing: a comparison of postthaw and postwash samples. Transfusion. 2005;45:1909-16.
15. + cell enumeration by flow cytometry: results of a pair-wise analysis of umbilical cord blood units and cryopreserved aliquots. Transfusion. 2009;49: 636-47.